BIOMAT Database Logo BIOMAT Database Logo

Validation of Minnesota acute graft-versus-host disease Risk Score. 2020

Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN macmi002@umn.edu.

Using multicenter data, we developed a novel acute graft-versus-host disease Risk Score which more accurately predicts response to steroid treatment, survival and transplant related mortality than other published risk scores based upon clinical grading criteria.1 To validate this Risk Score in a contemporary cohort, we examined 355 recent University of Minnesota patients (2007-2016) diagnosed with acute graft-versus-host disease and treated with prednisone 60 mg/m2/day for 14 days, followed by an 8-week taper. Overall response [complete response + partial response] was higher in the 276 standard risk versus 79 high risk graft-versus-host disease patients at day 14 (71% versus 56%, P<0.01), day 28 (74% versus 59%, P=0.02) and day 56 (68% versus 49%, P<0.01) after steroid initiation. Day 28 response did not differ by the initial graft-versus-host disease grade. In multiple regression analysis, patients with high risk graft-versus-host disease were less likely to respond at day 28 (odds ratio 0.5, 95% CI 0.3-0.9, P<0.01) and had higher risks of 2 year transplant related mortality (Hazard Ratio 1.8, 95% CI, 1.0-2.1, P=0.03) and overall mortality (Hazard Ratio 1.7, 95% CI, 1.2-2.4, P<0.01) than patients with a standard risk graft-versus-host disease. This analysis confirms the Minnesota graft-versus-host disease Risk Score as a valuable bedside tool to define risk in patients with acute graft-versus-host disease. A tailored approach to upfront acute graft-versus-host disease therapy based upon the Minnesota Risk Score may improve outcomes and facilitate testing of novel treatments in these patients.

UI MeSH Term Description Entries
D008910 Minnesota State bordered on the north by Canada, on the east by Lake Superior and Wisconsin, on the south by Iowa, and on the west by North Dakota and South Dakota.
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell

Related Publications

Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis.
November 2022, Haematologica,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Risk factors for acute graft-versus-host disease.
December 1987, British journal of haematology,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute graft-versus-host disease.
January 1990, Cancer treatment and research,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute graft-versus-host disease.
December 2011, Immunotherapy,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute graft versus host disease.
January 2011, Indian journal of dermatology, venereology and leprology,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute graft-versus-host disease.
June 2023, Nature reviews. Disease primers,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute graft-versus-host disease.
June 2023, Nature reviews. Disease primers,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute Graft-versus-Host Disease.
February 2018, The New England journal of medicine,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute Graft-versus-Host Disease.
February 2018, The New England journal of medicine,
Margaret L MacMillan, and Todd E DeFor, and Shernan G Holtan, and Armin Rashidi, and Bruce R Blazar, and Daniel J Weisdorf
Acute graft versus host disease.
September 2007, Orphanet journal of rare diseases,
Copied contents to your clipboard!